Core Viewpoint - Aomei Medical (002950.SZ) expects a significant decline in net profit for 2025, projecting a range of 215.50 million to 257.50 million yuan, representing a decrease of 30.16% to 41.55% compared to the previous year [1] Group 1: Financial Projections - The net profit attributable to shareholders is forecasted to be between 215.50 million and 257.50 million yuan, indicating a decline of 30.16% to 41.55% year-on-year [1] - The net profit excluding non-recurring gains and losses is expected to be between 179.50 million and 221.50 million yuan, reflecting a decrease of 35.49% to 47.72% compared to the previous year [1] Group 2: Business Strategy - The company will adhere to a "dual-wheel drive" strategy focusing on both domestic and international markets to steadily build a new business growth foundation [1] - Aomei Medical aims to actively expand into functional dressings and healthcare products while continuing to promote sales in these areas [1] - The company's overseas business has effectively mitigated the impact of international trade conflicts, maintaining growth by entering new markets and channels [1]

Core Viewpoint - Aomei Medical (002950) reported a revenue of 2.597 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 5.98%, and a net profit attributable to shareholders of 349 million yuan, up 31.54% [1] Group 1: Financial Performance - In Q3 2025, the company achieved a revenue of 920 million yuan, with a year-on-year increase of 5.97%, and a net profit of 149 million yuan, reflecting a significant growth of 90.57% [1] - The company has maintained steady growth in performance while focusing on its core business and expanding into functional dressings, hospital infection prevention products, and hygiene care products [1] Group 2: Business Overview - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection prevention products, and home care products, being the only global enterprise with integrated, large-scale, and intelligent production in medical dressings and infection prevention products [1] - The company has been the leading exporter of medical dressings in China for 17 consecutive years since 2008, focusing on increasing its market share in overseas markets [2] Group 3: Product Development - The company is expanding its product line to include advanced dressing products, with a series of medical wound care products set to launch in 2024, including soft silicone foam dressings, hydrocolloid dressings, transparent dressings, and silicone gel scar patches [2] - Infection prevention products are designed for scenarios such as hospital infection control and surgical room management, with expectations for increased market penetration due to growing domestic emphasis on infection prevention [2] - Hygiene care products represent an extension of the company's medical device offerings into home care, although the brand presence in this category is still relatively small and in the early stages of development [2]